Swedish pharmaceutical company Medivir AB (STO:MVIR) announced on Monday that it has entered into a clinical trial collaboration and supply agreement with Japan's Eisai Co Ltd (TYO:4523) to evaluate fostrox in combination with lenvatinib in a Phase 2b study for second-line advanced liver cancer.
The combination therapy has shown encouraging anti-tumour activity and a manageable safety profile in a previous Phase 1b/2a study, with a median time to progression of 10.9 months.
Fostrox, an oral, liver-targeted treatment, has the potential to become a significant therapeutic option for patients with advanced liver cancer.
The collaboration with Eisai will allow Medivir to accelerate the development of fostrox and address a significant unmet medical need.
Sichuan Kelun-Biotech's sacituzumab tirumotecan receives Chinese regulatory approval
Compugen receives new patent covering COM902 use
Natera Ssecures Medicare coverage for Prospera in single lung transplant patients
TheraCryf receives European patent for Orexin 1 antagonist
Oxford Nanopore and UK Biobank partner to create world's largest epigenetic dataset
Novartis' Kisqali approved in EU for broader population of high-risk early breast cancer patients
Duality Biologics expands collaboration with Adcendo ApS
GSK plc announces US FDA acceptance of review for Blenrep combinations in multiple myeloma
AstraZeneca reports improved rPFS with Truqap in advanced prostate cancer